DXR · Daxor Corporation Common Stock
View on chartInsiders & Stakes
| of Joseph Feldschuh Estate 10% Owner | ▼ Sell | Gift | 2,549,455 Shares held | 9/18/2023 | View profile |
| Michael Richard Feldschuh CEO & President | ▲ Buy | Grant | 243,694 Shares held | 6/23/2026 | View profile |
| Jonathan Adam Feldschuh Chief Scientific Officer | ▲ Buy | Grant | 78,908 Shares held | 6/23/2026 | View profile |
| Robert J. Michel Chief Financial Officer | ▲ Buy | Grant | 33,050 Shares held | 6/23/2026 | View profile |
| John Jefferies Chief Medical Officer | ▲ Buy | Grant | 26,008 Shares held | 8/28/2026 | View profile |
| DesRosiers Caleb Director | ▲ Buy | Open Market | 3,157 Shares held | 11/17/2022 | View profile |
| Edward Feuer Director | ▲ Buy | Open Market | 1,000 Shares held | 3/4/2024 | View profile |
| Goudie Joy S. Director | ▲ Buy | Open Market | 300 Shares held | 5/24/2023 | View profile |
Transaction History
| John Jefferies | ▲ Buy | Grant | 2,451 | $0 | 8/28/2026 |
| Robert J. Michel | ▲ Buy | Grant | 12,000 | $0 | 6/23/2026 |
| Michael Richard Feldschuh | ▲ Buy | Grant | 30,000 | $0 | 6/23/2026 |
| Jonathan Adam Feldschuh | ▲ Buy | Grant | 25,000 | $0 | 6/23/2026 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 1,000 | $9K | 4/8/2026 |
| Robert J. Michel | ▲ Buy | Open Market | 1,000 | $10K | 3/31/2026 |
| John Jefferies | ▲ Buy | Open Market | 3,656 | $0 | 3/20/2026 |
| John Jefferies | ▲ Buy | Open Market | 2,285 | $0 | 3/20/2026 |
| Robert J. Michel | ▲ Buy | Open Market | 3,000 | $0 | 12/9/2025 |
| Jonathan Adam Feldschuh | ▲ Buy | Open Market | 18,000 | $0 | 12/9/2025 |
| John Jefferies | ▲ Buy | Open Market | 2,344 | $0 | 11/12/2025 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 2,063 | $16K | 4/4/2025 |
| Robert J. Michel | ▲ Buy | Open Market | 1,000 | $8K | 3/10/2025 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 3,360 | $26K | 3/10/2025 |
| Jonathan Adam Feldschuh | ▲ Buy | Open Market | 32,000 | $0 | 12/6/2024 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 45,000 | $0 | 12/6/2024 |
| Robert J. Michel | ▲ Buy | Open Market | 750 | $7K | 3/27/2024 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 1,000 | $8K | 3/26/2024 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 647 | $5K | 3/19/2024 |
| Edward Feuer | ▲ Buy | Open Market | 1,000 | $7K | 3/4/2024 |
| Robert J. Michel | ▲ Buy | Open Market | 120 | $930 | 12/6/2023 |
| Robert J. Michel | ▲ Buy | Open Market | 180 | $1K | 12/1/2023 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 800 | $6K | 12/1/2023 |
| Robert J. Michel | ▲ Buy | Open Market | 500 | $4K | 11/24/2023 |
| Michael Richard Feldschuh | ▲ Buy | Grant | 84 | $643 | 11/21/2023 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 1,001 | $8K | 11/10/2023 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 401 | $3K | 11/9/2023 |
| Robert J. Michel | ▲ Buy | Grant | 2,000 | $0 | 10/31/2023 |
| Robert J. Michel | ▲ Buy | Open Market | 500 | $5K | 10/13/2023 |
| of Joseph Feldschuh Estate | ▼ Sell | Gift | 25,000 | $0 | 9/18/2023 |
| Michael Richard Feldschuh | ▲ Buy | Open Market | 2,000 | $20K | 5/24/2023 |
| Goudie Joy S. | ▲ Buy | Open Market | 300 | $3K | 5/24/2023 |
| Robert J. Michel | ▲ Buy | Open Market | 4,750 | $0 | 3/27/2023 |
| Robert J. Michel | ▲ Buy | Open Market | 1,000 | $10K | 11/18/2022 |
| DesRosiers Caleb | ▲ Buy | Open Market | 3,157 | $30K | 11/17/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026
Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.
Daxor to Present New Blood Volume Analyzer and Data at HFSA 2026. Daxor Corporation announced it will showcase its next-generation blood volume analyzer and share new clinical data at the HFSA 2026 conference. This presentation highlights the company's focus on advancing its medical technology offerings. The stock is currently trading near its 200-day moving average, with an average analyst target of $20.00.